NCT01194960 - TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Hormone Refractory Prostate Cancer

Interventions

DRUG

Docetaxel

Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.

DRUG

TroVax

Trovax on Days 1,10, 22 and then Weeks 7, 10, 13, 19, 25, 31 and 37

Trial Locations (7)

New York University Cancer Institute, New York

Charleston Hematology Oncology Associates, Charleston

Gabrail Cancer Center Research, Canton

Rush University Medical Center, Chicago

GU Research Network, Omaha

San Bernardino Urology, San Bernardino

Stanford University Medical Center, Stanford